A Investigator-initiated Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Relapsed/Refractory Primary Immune Thrombocytopenia
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Daratumumab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 May 2025 Planned number of patients changed from 20 to 60.
- 28 May 2025 Status changed from recruiting to active, no longer recruiting.
- 24 Feb 2025 Protocol was amended as phase changed from early phase 1 to phase 2, and time frame of primary endpoint changed from 9-24 weeks to 8 weeks.